By Hongjiang Li, Staff Writer | Jul 19, 2019 | 12:04 AM GMT
European bellwether Genmab plans to use a large chunk of the $505.9 million it raised through its listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC).
Read the full 331 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD